

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF Naomi ASAHLARA, et al.

SERIAL NO: 10/588,513

GAU: 1614

FILED: August 4, 2006

EXAMINER:

FOR: PHARMACEUTICAL FORMULATIONS COMPRISING PARAOXONASE

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the reference(s) listed on the attached form PTO-1449. Copies of the listed reference(s) are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language reference(s).
- Online credit card payment is being made in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- Online credit card payment is being made in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

Richard D. Kelly

Registration No. 27,757

Customer Number

22850

Tel (703) 413-3000  
Fax (703) 413-2220  
(OSMMN 05/03)

Akihiro Yamazaki  
Registration No. 46,155

JAN 2007  
Registration No. 22,630

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RAD/

DOCKET NO.: 294625US40PCT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF:

Naomi ASAHLARA, et al.

SERIAL NO: 10/588,513

GROUP: 1614

FILED: August 4, 2006

EXAMINER:

FOR: PHARMACEUTICAL FORMULATIONS COMPRISING PARAOXONASE

**STATEMENT OF RELEVANCY**

References AO to AP and AS to AX are cited in the specification.

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. <b>294625US40PCT</b>		SERIAL NO. <b>10/588,513</b>	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT <b>Naomi ASAHLARA, et al.</b>			
				FILING DATE <b>August 4, 2006</b>		GROUP <b>1614</b>	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	6,391,298 B1	05/21/2002	Klaus-Peter RADTKE			
	AB	2003/0027759 A1	02/06/2003	Klaus-Peter RADTKE			
	AC	6,521,226 B1	02/18/2003	Klaus-Peter RADTKE			
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
	AO	WO 00/30425	06/02/2000	WIPO (corr. US 6,391,298 B1, US 2003/0027759 A1 and US 6,521,226 B1)	YES		NO
	AP	JP 2000-333674	12/05/2000	JAPAN (with English Abstract)			X
	AQ						
	AR						
<b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
	AS	Michael AVIRAM, et al., "Paraoxonase Inhibits High-density Lipoprotein Oxidation and Preserves its Functions", J. Clin. Invest., Vol. 101, No. 8, April 1998, Pages 1581-1590					
	AT	Diana M. SHIH, et al., "Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis", Letters to Nature, Vol. 394, July 16, 1998, Pages 284-286					
	AU	RC SORENSEN, et al., "Reconsideration of the Catalytic Center and Mechanism of Mammalian Paraoxonase/Arylesterase", Proceedings of the National Academy of Sciences of the United States of America, Vol. 92, August 1995, Pages 7187-7191					
	AV	Robert J. BRUSHIA, et al., "Baculovirus-mediated expression and purification of human serum paraoxonase 1A", Journal of Lipid Research, Vol. 42, 2001, Pages 951-958					
	AW	H. NAGASAWA, et al., "Correlation between cerebral blood flow and histologic changes in a new rat model of middle cerebral artery occlusion", Stroke, Vol. 20, No. 8, August 1989, Pages 1037-1043 with cover page					
	AX	Yi LI, et al., "Intrastriatal Transplantation of Bone Marrow Nonhematopoietic Cells Improves Functional Recovery After Stroke in Adult Mice", Journal of Cerebral Blood Flow and Metabolism, Vol. 20, No. 9, 2000, Pages 1311-1319				<input type="checkbox"/> Additional References sheet(s) attached	
Examiner <b>/Ruth A. Davis/ (05/22/2010)</b>				Date Considered <b>05/22/2010</b>			
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RAD/